See feature articles below: (NASDAQ:EBIO)
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
–Report on: (NASDAQ:EBIO)
Trade-Ideas LLC identified Eleven Biotherapeutics ( EBIO) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Eleven Biotherapeutics as such a stock due to the following factors:
EBIO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $7.5 million.
EBIO has traded 5.1 million shares today.
EBIO is trading at 42.18 times the normal volume for the stock at this time of day.
EBIO is trading at a new high 43.14% above yesterday’s close.
‘Strong on High Relative Volume’ stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from ‘superinvestors,’ or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
Eleven BiotherapeuticsInc (EBIO) on April 29, 2016announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.
Eleven Biotherapeutics’ most advanced preclinical product candidate is EBI-031 for treatment of diabetic macular edema, or DME, and uveitis. EBI-031 was designed and engineered for intravitreal delivery using Eleven’s AMP-Rx platform. EBI-031 is a potent blocker of both free IL-6 and IL-6 complexed to the soluble IL-6 receptor (IL-6R) and has demonstrated a longer vitreal retention time in preclinical models than antibodies and antibody like molecules approved for intravitreal injection. Eleven is undertaking the necessary manufacturing development work and nonclinical safety studies to support the submission of an investigational new drug application, or IND, to the FDA in the first half of 2016 for the purpose of conducting clinical trials of EBI-031 in DME and uveitis.
A price target is a projected price level as stated by an investment analyst or advisor.
A Number of brokers believe that the price target for the company may go as high as $12.00 whereas, the low target suggested by the brokers is $12.00 . The Mean Price Target for the Stock by the brokers is at $12.00.
Earnings Estimate & Revenue Estimate of Eleven Biotherapeutics Inc (NASDAQ:EBIO) for the Current Quarter Mar 16:
The Previous Year Earnings per Share (EPS) of this Quarter was $-0.36.
The Trend for 7 days ago was $-0.21. The EPS Trend for 30, 60 and 90 Days ago were $-0.21, $-0.21 and $-0.21 respectively.
The consensus EPS trend allows the investor to understand the recent direction of earnings estimates. The trend shows the investor how the estimates have been changing as new information is published by the company. Trends are usually shown for 90 days, 60 days, 30 days, and 7 days.
If the earnings estimates are declining over time, this is usually a signal that new information made an analyst revise their forecast downward. Generally, an investor wants to see values that remain steady or move in a positive direction.
While looking at Revenue estimate of the company, 1 analysts.
Source – The Street , ACAD Charts, News Oracle
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
